The maker of the anti-depressant Paxil agreed to pay $14 million to state drug-purchasing programs to settle allegations that it blocked generic versions of the drug from being made, causing the states to pay higher prices.

A spokeswoman for GlaxoSmithKline said the company denied any wrongdoing and was not admitting liability in making the settlement, which mostly affects Medicaid programs.